Current and future therapies for HCV infection: What should the end point for treatment be?

Hepato-Gastroenterology

Volumn 45, Issue 20, 1998, Pages 308-320

  Van Thiel, David H ^a,b   De Maria, Nicola ^a   Colantoni, Alessandra ^a   Idilman, Ramazan ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; AMANTADINE; ANTIVIRUS AGENT; COLCHICINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; S ADENOSYLMETHIONINE; URSODEOXYCHOLIC ACID;

BLOOD TRANSFUSION; DISEASE COURSE; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; NEEDLESTICK INJURY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REVIEW; RISK FACTOR; SCORING SYSTEM; SEXUAL TRANSMISSION; SIDE EFFECT; SUICIDE ATTEMPT; TIME; VIRUS GENOME; VIRUS LOAD; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; PREVALENCE;

EID: 0031971864     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Choo QL, Richman KH, Han JH, Berger K, Lee C et al: Genetic organization and diversity of the hepatitis C virus. Proc Natl Aca Sci USA 1991; 15:2451-5.
2. Houghton M, Weiner AJ, Han J, Kuo G, Choo QL: Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991; 14:381-8.
3. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B et al: Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74:2391-9.
4. Kato N, Ootsuyama Y, Sekiya H, Ohkoshi S, Nakazawa T, Hijikata M et al: Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol 1994; 68:4776-84.
5. Alter MJ: Epidemiology of hepatitis C in the West. Semin Liver Dis 1996; 15:5-14.
6. Stevens CE, Taylor PE, Pindyck J, Choo QL, Bradley DW, Kuo G et al: Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors. JAMA 1990; 263:49-53.
7. Alter MJ, Hadler SC, Judson FN, Mares A, Alexander WJ, Hu PY et al: Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264:2231-5.
8. Sharara AI, Hunt CM, Hamilton JD: Hepatitis C. Ann Intern Med 1996; 125:658-668.
9. Esteban JI, Lopez-Talavera JC, Genesca J, Madoz P, Viladomiu L, Muniz E et al: High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115:443-9.
10. Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K et al: Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991; 115:367-9.
11. Mitsui T, Iwano K, Masuko K, Yamazaki C, Okamoto H, Tsuda F et al: Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992; 16:1109-14.
12. Ko YC, Ho MS, Chiang TA, Chang SJ, Chang PY: Tattooing as a risk of hepatitis C virus infection. J Med Virol 1992; 38:288-91.
13. Liou TC, Chang TT, Young KC, Lin XZ, Lin CY, Wu HL: De tection of UCV RNA in saliva, urine, seminal fluid, and ascites. J Med Virol 1992; 37:197-202.
14. Thomas DL, Zenilman JM, Alter JH, Shih JW, Galai N, Carella AV et al: Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - an analysis of 309 sex partnerships. J Infect Dis 1995; 171:768-75.
15. Akahane Y, Kojima M, Sugai Y, Sakamoto M, Miyazaki Y, Tanaka T et al: Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med 1994; 120:748-52.
16. Lin HH, Kao JH, Hus HY, Ni YH, Yeh SH, Hwang LH, Chen DS: Possible role of high-titer maternal niremia in perinatal transmission of hepatitis C virus. J Infect Dis 1994; 169:638-641.
17. Ohio H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C et al: Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330:744-50.
18. Ideo G, Bellati G, Pedraglio E, Bottelli R, Donzelli T, Putignano G: Intrafamilial transmission of hepatitis C virus [Letter]. Lancet 1990; 112:544-5.
19. Camarero C, Martos I, Delgado R, Suzrez L, Escobar H, Mateos M: Horizontal transmission of hepatitis C virus in households of infected children. J Pediatr 1993; 123:98-9.
20. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T: Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88:240-243.
21. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-1466.
22. Obald SA, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, Di Bisceglie AM: Hepatitis C Study Group. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995; 123:330-337.
23. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ: Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991; 14:969-74.
24. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V et al: Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123:330-7.
25. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ et al: The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327:1899-905.
26. Gurakar A, Fagiuoli S, Wright HI, Van Thiel DH: Hepatitis C virus infection: When to suspect, how to detect. The Journal of Critical Illness 1993; 8:1287-1298.
27. Filipiak CL, Gordon SC, Silverman AL, Neill JS, Wilber JC: Low, normal or minimally raised ALT values do not predict viremic levels or histologic activity in patients with chronic hepatitis C [Abstract]. Hepatology 1994; 20:347A.
28. Shindo M, Arai K, Sokawa Y, Okuno T: The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995; 22:418-25.
29. Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H et al: Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994; 19:871-5.
30. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernana TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-5.
31. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagel JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Eng J Med 1989; 321:1506-10.
32. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HCJ, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch T, Albrecht J, Meschievitz C, Ortego T, Gibas A, and the Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 21:1501-6.
33. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr., Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A: The Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized controlled trial. J Hepatology 1990; 11:S31-S35.
34. Van Thiel DH, Gavaler JS, Baddour N, Friedlander L, Wright HI: Treatment of putative Non A, Non B, Non C hepatitis with -interferon: A preliminary trial. J Okla State Med Assoc 1994; 87.
35. Van Thiel DH: Current and future uses of biological response modifiers in the treatment of viral hepatitis. J Okla State Med Assoc 1994; 87:319-322.
36. Gholson CF, Fayrot D, Taylor B, Catinis G, Balart L: Chronic hepatitis C virus (HCV) infection and persistently normal aminotransferases (PNAC): a preliminary report of alfa interferon (IFN) resistance. Hepatology 1996; 24:401A (Abstract 1097).
37. Serfaty L, Chazouilleres O, Pawlotsky JM, Andreani T, Pellet C, Poupon R et al: Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology. 1996; 110:291-5.
38. Van Thiel DH, Caraceni P, Molloy PJ, Hassanein T, Kania RJ, Gurakar A, Nadir A, Friedlander L: Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: The role of interferon 2b therapy. Journal of Hepatology 1995; 23:503-508.
39. Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D et al: A multicenter randomized controlled trial of recombinant interferon alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994; 19:19-22.
40. Viladomiu L, Genesca J, Esteban JI, Allende H, Gonzalez A, Lopez-Talavera JC et al: Interferon-alpha in acute post-transfusion hepatitis C: a randomized, controlled trial. Hepatology 1992; 15:767-9.
41. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F et al: Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338:914-5.
42. Idilman R, De Maria N, Colantoni A, Dokmeci A, Van Thiel DH: Interferon treatment of cirrhotic patients with chronic hepatitis C. Journal of Viral Hepatitis 1997; 4:in press.
43. Samuel CE: Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991; 183:1-11.
44. Douglas DD, Rakela J, Lin HJ, Hollinger FB, Taswell HF, Czaja AJ, Gross J et al: Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci 1993; 38:601-607.
45. David E, Pucci A, Palladin D, Saracco G, Garello E, Pintus C, Rocca G et al: Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A, non-B viral hepatitis: a randomized controlled trial. Am J Clin Pathol 1992; 98:397-401.
46. Gurakar A, Fagiuoli S, Faruki H, De Maria N, Balkan M, Friedlander L, Van Thiel DH: Utility of HCV-RNA Determinations in Hepatic Tissue as an End Point for Interferon Treatment of Chronic Hepatitis C. Hepatology 1995; 22:1109-112.
47. Friedlander L, Van Thiel DH, Faruki H, Molloy PJ, Kania RJ, Hassanein T: New approach to HCV treatment recognition of disease process as systemic viral infection rather than as liver disease. Digestive Diseases and Sciences 1996; 41:1678-1681.
48. Shindo M, Di Bisceglie AM, Hoofnagle JH: Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992; 15:1013-6.
49. Young KC, Chang TT, Liou TC, Wu HL: Detection of hepatitis C virus RNA in peripheral blood mononuclear cells and in saliva. J Med Virol 1993; 41:55-60.
50. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A et al: Long-term follow-up of patients with chronic hepatitis C treated with different doses of Interferon-alfa2b. Hepatology 1993; 18:1300-1305.
51. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi S et al: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22:700-706.
52. Vogel W, Umlauft F, Datz C, Judmaier G, Shneider G, Gruneward K et al: High dose interferon alpha for acute hepatitis C [Abstract]. Hepatology 1993; 14:89A.
53. Van Thiel DH, Friedlander L, Fagiuoli S, Molloy P, Kania RJ, Wright HI: The Oklahoma-Pittsburgh Experience with Interferon in the Treatment of HCV Disease. J Okla State Med Assoc 1995; 88:154-161.
54. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S: Treatment of chronic hepatitis C with high-dose interferon ?-2b: a multicenter study. Digestive Diseases and Sciences 1993; 38:612-618.
55. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A et al: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994; 19:280-5.
56. Qian C, Camps J, Maluenda M et al: Replication of hepatitis C virus in peripheral blood mononuclear cells: Efect of alpha interferon therapy. J Hepatol 992; 16:380-3.
57. Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F et al: Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19:841-8.
58. Pawlotsky JM, Roudot-Thorval F, Simmonds P, Mellor J, Ben Yahia MB, Andre C et al: Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995; 122:169-73.
59. Todros L, Touscoz G, D'Urso N, Durazzo M, Albano E, Poli G et al: Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). Clinical characterization from idiopathic LKM-positive disorders. J Hepatol 1991; 13:128-31.
60. Michel G, Ritter A, Gerken G, Meyer zum Buschenfelde KH, Decker R, Manns MP: Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet 1992; 339:267-9.
61. Agnelle V, Vhung RT, Kaplan LM: A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490-5.
62. Misiani R, Bellaviat P, Fenili D, Vicari O, Marchesi D, Sironi PL et al: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751-6.
63. Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D et al: Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339:321-3.
64. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P et al: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465-70.
65. Moazami G, Auran JD, Florakis GJ, Wilson SE, Srinivasan DB: Interferon treatment of Mooren's ulcers associated with hepatitis C. Am J Ophthalmol 1995; 119:365-6.
66. Wilson SE, Lee WM, Murakami C, Went J, Moninger GA: Mooren-type hepatitis C virus-associated corneal ulceration. Ophthalmology 1994; 101:736-45.
67. Sidwell R, Huffman JH, Khare L, Allen LB, Witlowski JT, Robins RK: Broad-spectrum activity of virazole: 1-beta-Dribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 117:705-6.
68. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O: Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol 1996; 25:591-598.
69. Reichard O, Yun ZB, Sonnerborg A, Weiland O: Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41:99-102.
70. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH: Rivavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:897-903.
71. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L: A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107:812-817.
72. Schvarcz R, Yun ZB, Sonnerborg, Weiland O: Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Vir 1995; 46:43-47.
73. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS: Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111:1307-1312.
74. Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J, Russo A, Colombo M: A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996; 24:1366-1370.
75. Takano S, Ito YT, Yokosuka O, Ohto M, Uchiumi K, Hirota K et al: A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20:558-64.
76. Andreone P, Cursaro C, Gasbarrini G: Interferon-a increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 1993; 19:228-31.
77. Andreone P, Cursaro C, Gramenzi A, Buzzi A, Semeraro R, Bernardi M et al: Pilot study of a-interferon and ketoprofen combined therapy in non-responder patients with chronic hepatitis C: An interim report [Abstract]. Gastroenterology 1994; 106:A859.
78. Barbaro G, Di Lorenzo G, Soldini M, Parrotto S, Bellomo G, Belloni G, Benvenuto G, Barbarini G: Hepatic glutathione deficiency in chronic hepatitis C; quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol 1996; 12:2569-2573.
79. Suarez M, Beloqui O, Ferrer VJ et al: Glutathione depletion in chronic hepatitis C. Int Hepatol Commun 1993; 1:215-21.
80. Beloqui O, Prieto J, Suarez M et al: N-Acetyl-cysteine enhances the response to interferon a in chronic hepatitis C: a pilot study. J Interferon Rex 1993; 13:279-82.
81. De Maria N, Colantoni A, Fagiuoli S, Liu GJ, Rogers BK, Farinati F, Van Thiel DH, Floyd RA: Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radical Biology & Medicine 1996; 21:291-295.
82. Beloqui O, Prieto J, Suarez M, Gil B, Qian CH, Garcia N et al: N-acetylcysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res 1993; 13:279-82.
83. Felton C, Lustbader ED, Merten C, Blumberg BS: Serum iron levels and response to hepatitis B virus. Proc Natl Acad Sci USA 1979; 76:2438-41.
84. Blumberg BS, Lustbader ED, Whitford PL: Changes in serum iron levels due to infection with hepatitis B virus. Proc Natl Acad Sci USA 1982; 78:3222-4.
85. Arber N, Konikoff FM, Moshkowitz M, Baratz M, Hallak A, Santo M, Halpern Z, Weiss H, Gilat T: Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994; 39:2656-9.
86. Lustbader ED, Hann HW, Blumberg BS: Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983; 220:423-5.
87. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS: Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20:410-5.
88. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE: Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996; ?? Author please give volume no.:633-638.
89. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, Faa G, Diana G, Dessi C: Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. Pediatr 1994; 125:123-8.
90. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, Faa G, Diana G, Dessi C: Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. Pediatr 1994; 125:123-8.
91. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N: Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89:986-8.
92. De Castro M, Sanchez J, Herrera JF, Chaves A, Duran R, Garcia-Buey L et al: Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17:551-7.
93. Bayraktar Y, Koseoglu T, Somner C, Kayhan B, Temizer A, Uzunalimoglu B, De Maria N, Van Thiel DH: The use of deferoxamine infusions to enhance the response rate to interferon alpha treatment of chronic viral hepatitis B. J Viral Hepatitis 1996; 3:129-135.
94. Gurakar A, Fagiuoli S, Gavaler JS, Hassanein T, Jabbour N, Wright HI, Deal SA, Shah A, Brown M, Carr BI, Van Thiel DH: The use of granulocyte-macrophage colony-stimulating factor to enhance hematologic parameters of patients with cirrhosis and hypersplenism. Journal of Hepatology 1994; 21:582-586.
95. Wright HI, Gavaler JS, Baddour N, Van Thiel DH: Granulocyte colony stimulating factor (GCSF) combined with interferon for the treatment of liver allograft recipients with viral hepatitis. J of Hep (letter) 1994; 21:915-916.
96. Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, Kania RJ, Wright HI: Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepato-Gastroenterology 1995; 42:907-912.